These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 11989593)
1. Mitomycin C and vinblastine in anthracycline-resistant metastatic breast cancer: a phase II study. Kalofonos HP; Onyenadum A; Kosmas C; Koutras A; Petsas T; Efthimiou V; Koukouras D; Tzoracolefterakis E; Andrikopoulos P; Androulakis J Tumori; 2001; 87(6):394-7. PubMed ID: 11989593 [TBL] [Abstract][Full Text] [Related]
2. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538 [TBL] [Abstract][Full Text] [Related]
3. Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). Kusenda Z; Kerger J; Awada A; Geurs F; Van Vreckem A; Habboubi N; Piccart MJ Support Care Cancer; 1997 Sep; 5(5):414-6. PubMed ID: 9322355 [TBL] [Abstract][Full Text] [Related]
4. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353 [TBL] [Abstract][Full Text] [Related]
5. Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patients. Ospovat I; Siegelmann-Danieli N; Grenader T; Hubert A; Hamburger T; Peretz T Tumori; 2009; 95(6):683-6. PubMed ID: 20210229 [TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea did not enhance the clinical response to vinblastine in patients with anthracycline-resistant metastatic breast cancer. Huan SD; Yau JC; Tomiak E; Goel R; Cripps C; Gertler SZ; Prosser IA; Stewart DJ Tumori; 1996; 82(6):576-8. PubMed ID: 9061067 [TBL] [Abstract][Full Text] [Related]
7. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment. Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438 [TBL] [Abstract][Full Text] [Related]
8. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489 [TBL] [Abstract][Full Text] [Related]
9. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial. Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183 [TBL] [Abstract][Full Text] [Related]
10. Mitomycin C and vinorelbine in pretreated breast cancer. Colleoni M; Manente P; Stocker J; Amor H; Lamon S; Nelli P; Vicario G; Sgarbossa G; Graiff C Tumori; 1997; 83(5):834-6. PubMed ID: 9428918 [TBL] [Abstract][Full Text] [Related]
11. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group. Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G Oncology; 2001; 60(2):127-33. PubMed ID: 11244327 [TBL] [Abstract][Full Text] [Related]
12. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Vassilomanolakis M; Koumakis G; Barbounis V; Demiri M; Pateras H; Efremidis AP Ann Oncol; 2000 Sep; 11(9):1155-60. PubMed ID: 11061611 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy. Rosati G; Riccardi F; Tucci A; De Rosa P; Pacilio G Tumori; 2000; 86(3):207-10. PubMed ID: 10939600 [TBL] [Abstract][Full Text] [Related]
14. Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma. Agostara B; Gebbia V; Testa A; Cusimano MP; Gebbia N; Callari AM Tumori; 1994 Feb; 80(1):33-6. PubMed ID: 8191595 [TBL] [Abstract][Full Text] [Related]
15. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. Martín M; Lluch A; Casado A; Garciía Carbonero I; de Paz L; Esteban C; Insa A; Alfonso R; García-Conde J; Diaz-Rubio E Ann Oncol; 2000 Jan; 11(1):85-9. PubMed ID: 10690393 [TBL] [Abstract][Full Text] [Related]
16. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543 [TBL] [Abstract][Full Text] [Related]
17. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Klaassen U; Wilke H; Seeber S Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897 [TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049 [TBL] [Abstract][Full Text] [Related]
19. Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study. Polyzos A; Tsavaris N; Kosmas C; Gogas H; Toufexi H; Kosmidis C; Markopoulos C; Giannopoulos A; Papadopoulos O; Stamatiadis D; Kouraklis G J Chemother; 2003 Dec; 15(6):607-12. PubMed ID: 14998089 [TBL] [Abstract][Full Text] [Related]
20. A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action. Kim R; Osaki A; Tanabe K; Kojima J; Toge T Oncol Rep; 2001; 8(3):597-603. PubMed ID: 11295087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]